CRISPR Clinical Trials: A 2026 Update
promising phase-one trials for base-editing therapeutics (such as those targeting APOC3 to lower cardiovascular disease risks), experimental gene therapies to slow aging-related vision loss via epigenetic reprogramming, and a postnatal therapy for congenital hearing loss